Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Lin Shen et al.|Annals of Oncology|2019Cited by 475
Danhong Injection targets CaMKII through Dihydrotanshinone I to alleviate cardiomyocyte death and inflammation in viral myocarditisJunxia Zhang, Yan Zhang, Chengcheng Zhao et al.|Science China Life Sciences|2025Cited by 2